Obexelimab Reduces Disease Flares and Steroid-Toxicity in IgG4-RD
An exciting Phase 3 trial has confirmed that obexelimab significantly reduces the risk of disease flare in IgG4-related disease (IgG4-RD) while also delivering measurable reductions in ...
Steroid-Sparing Is Not Enough: GCA Trials Need Toxicity Data
New phase 3 data from the GCAptAIN trial show that secukinumab enabled a shorter steroid taper, less exposure, and meaningfully lower steroid-toxicity in giant cell arteritis (GCA). Although the ...
Secukinumab Delivers Sustained Remission and Toxicity Reduction in PMR
For the majority of patients with polymyalgia rheumatica, glucocorticoids do not provide a durable solution. They induce remission, but they do not maintain it. REPLENISH, the largest PMR clinical ...
The Lifetime Cost of Long-Term Steroids
A microsimulation model has quantified what clinicians have long suspected: sustained steroid exposure in autoimmune disease carries a measurable, and avoidable, clinical and economic burden that ...
In Conversation With… Mark Kosinski
“Measurement matters, but only when it changes decisions.” Patient-reported outcome science has spent three decades proving that what patients experience is as important as what clinicians observe. ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
